Choosing the first MS treatment: turning an initial prescription into a workable plan

First-line treatment does not necessarily mean every person with MS must begin with the same lower-intensity medicine. The first long-term strategy should fit the disease course, activity, safety factors, and personal circumstances. Earlier use of a high-efficacy treatment can be part of that discussion. The recommendation should explain why the proposed starting point is appropriate and how it will be reviewed.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The evidence should be sufficiently clear before committing to long-term immune treatment. A single clinical event, atypical imaging, or disagreement between hospitals may warrant checking which findings support the diagnosis and which alternatives remain plausible. The revised criteria allow earlier diagnosis in selected circumstances; they do not remove the need to exclude a better explanation. 2024 revised McDonald criteria
Before some immune treatments, the team will review vaccination records and consider outstanding immunizations, live vaccines, and timing. ECTRIMS and EAN recommendations support treatment-specific planning. There is no single waiting interval that applies to every vaccine and every DMT. MS vaccination consensus
The plan should identify the medicine by generic name, the indication being treated, outstanding screening, first administration, monitoring, and an urgent contact route. The Chinese guideline provides a local clinical framework, while subsequent diagnostic and drug developments require separate checking. Historical access descriptions should not be treated as current guarantees. Chinese MS diagnosis and treatment guideline

Quick answer

Full guide

A newly diagnosed patient may be managing an attack, unfamiliar test results, and changes to everyday life at once. Aim to leave the consultation knowing how the immediate problem will be treated, when maintenance therapy could start, what remains to be completed, and who will review subsequent results. A drug name alone is not the whole plan.

Confirm the diagnosis the treatment is intended to address

The evidence should be sufficiently clear before committing to long-term immune treatment. A single clinical event, atypical imaging, or disagreement between hospitals may warrant checking which findings support the diagnosis and which alternatives remain plausible. The revised criteria allow earlier diagnosis in selected circumstances; they do not remove the need to exclude a better explanation. 2024 revised McDonald criteria

If important results are outstanding, ask which decisions need immediate action and which can reasonably wait. Not every result must always arrive together, but a result that could substantially change the maintenance strategy should not be ignored merely to start quickly. The treating team should explain the clinical urgency.

Address the current attack separately from future disease control

When vision, walking, or self-care is substantially affected, the clinician may need to treat an acute relapse. Decisions about corticosteroids or other acute care depend on functional impact, safety considerations, and possible infection. Improvement after a short course does not establish that future disease activity is adequately managed. NICE relapse-management recommendations

Report previous steroid-associated sleep, glucose, mood, or infection problems. If treatment was given elsewhere, provide the actual medicine, doses, and dates. “Several days of injections” is not enough to determine what has already been done. Rehabilitation needs following the event can be assessed alongside the maintenance discussion.

Require a reason for the first DMT choice

Disease-modifying therapy, or DMT, is chosen using the disease course, recent clinical and MRI activity, recovery, relevant illnesses, and patient preferences. The AAN guideline supports shared decision-making and structured monitoring, but its publication date means it is not a complete inventory of medicines available in 2026. Current product information still needs to be checked. AAN DMT practice guideline

An escalation approach and earlier high-efficacy treatment involve different benefit-risk considerations. The 2025 expert consensus encourages serious discussion of earlier high-efficacy therapy in suitable patients. Ask which features make delayed escalation potentially costly and which safety concerns require attention before a more intensive strategy. Early high-efficacy treatment consensus

Symptoms alone cannot determine treatment intensity. A person who currently feels well may have imaging or historical evidence relevant to future risk. Conversely, prominent fatigue does not automatically establish a need for the highest-intensity DMT. It deserves assessment and symptom management in its own right.

Use trial evidence for the comparison it actually makes

OPERA compared ocrelizumab with interferon beta-1a in the enrolled relapsing-MS population and found differences in disease activity and selected progression outcomes. Its evidence concerns that comparison, with infusion reactions and the duration of observation also relevant to interpretation. Original OPERA randomized trials

ASCLEPIOS compared ofatumumab with teriflunomide and reported differences in annualized relapse rate and other outcomes. Its comparator, participants, and design were not identical to OPERA. Combining headline figures from the two programmes does not produce a valid ranking of every MS medicine. Original ASCLEPIOS randomized trials

For treatment in China, distinguish evidence of efficacy, national approval, the indication relevant to the individual, and actual hospital availability. Discuss specific feasible candidates rather than requesting another person's overseas prescription. Cost and convenience belong in the decision, alongside a careful assessment of benefit and harm.

Complete the safety work that determines readiness

Different DMTs may require different laboratory, infection, or other assessments. Additional screening can identify a problem that can be addressed before treatment; it does not automatically mean a medicine is unsuitable. If something is abnormal, establish who will evaluate it and when readiness will be reconsidered.

The Chinese ocrelizumab information, for example, specifies treatment-related assessment and precautions concerning infection and infusion management. Appropriate facilities must be available to manage relevant reactions. This can inform questions about the receiving centre's process, but one product's requirements cannot be generalized to every MS therapy. Chinese ocrelizumab prescribing information

Provide a complete list of prescribed medicines, non-prescription products, and supplements, together with important infections and liver or other medical history. Omitting information to avoid a possible delay makes planning less reliable. The purpose of preparation is to make the chosen treatment sustainable and appropriately monitored.

Connect vaccination planning to the proposed medicine

Before some immune treatments, the team will review vaccination records and consider outstanding immunizations, live vaccines, and timing. ECTRIMS and EAN recommendations support treatment-specific planning. There is no single waiting interval that applies to every vaccine and every DMT. MS vaccination consensus

Mention international travel plans early, including destination and timing. A travel vaccine may require coordination between services. After treatment has started, do not interrupt it independently to arrange vaccination. Identify who will reconcile advice from the vaccination service and the MS team.

Discuss reproductive plans before the first long-term prescription

Planning pregnancy, not currently planning it, and remaining undecided can each affect the discussion. Duration of a medicine's action, the consequences of withdrawal, and postpartum management may need advance preparation. The 2026 UK consensus update specifically addresses mechanisms, durable effects, and relapse risks associated with stopping treatment. 2026 MS pregnancy consensus update

This does not mean people with MS must abandon family plans or stop every medicine immediately when pregnancy occurs. Neurology and relevant specialists should consider disease activity, timing, and current Chinese prescribing information. Inform the team promptly about pregnancy or possible pregnancy so that individual advice can be provided.

Men's reproductive plans and practical family-care responsibilities also deserve discussion. Requirements differ by medicine. Another patient's washout interval or a special arrangement reported in research should not be copied into a personal plan without clinical review.

Match administration to a realistic routine

An oral treatment needs a reliable daily routine. Home injections may require training and suitable storage. Infusions involve appointments and observation. Explain likely difficulties such as shift work, frequent travel, limited hand function, or lack of accompaniment so the team can assess available support.

Test the plan against an ordinary disruption: a work trip, fever, or a delayed supply close to the next administration. Establish whom to contact for guidance. The solution should not depend on the patient independently bringing doses forward, making up missed treatment, or postponing it without advice.

Supply continuity should be checked before initiation. Receiving the first treatment in China does not guarantee access to the same medicine after returning home. Confirm whether a receiving clinician will continue the plan, whether required monitoring is available, and how subsequent medicine supply will be obtained lawfully and practically.

Establish the baseline needed for future decisions

Record important symptoms, examination or functional findings, and imaging suitable for comparison. Later, the clinician needs to know whether a change occurred before treatment, during the initial assessment period, or after stable treatment exposure. Standardized and comparable MRI supports that interpretation. MRI monitoring recommendations

Ask when efficacy will be reviewed, which symptoms warrant earlier contact, and how suspected activity will be confirmed. Someone should review normal results as well as abnormal ones. Put appointments and investigations into a calendar, including how results will reach the responsible clinician.

Start rehabilitation and symptom care where needed

Walking, hand use, or self-care difficulties after an attack may justify rehabilitation alongside DMT planning. Exercise recommendations should reflect ability and safety. Their role in everyday function does not establish that they replace disease-modifying treatment. MS exercise and physical-activity recommendations

Fatigue, pain, spasticity, urinary problems, and sleep difficulties also need a named plan. Tell the clinician which one or two issues currently matter most. This helps prevent a detailed maintenance-drug discussion from consuming the entire appointment while the most disruptive daily problem remains unaddressed.

Check the written plan before starting in China

The plan should identify the medicine by generic name, the indication being treated, outstanding screening, first administration, monitoring, and an urgent contact route. The Chinese guideline provides a local clinical framework, while subsequent diagnostic and drug developments require separate checking. Historical access descriptions should not be treated as current guarantees. Chinese MS diagnosis and treatment guideline

Request costs for the initial assessment, medicine and administration, follow-up, and possible additional care. Keep unconfirmed supply or insurance payment identified as unresolved. If a key condition is not ready, agree on a reasonable sequence for completing it. The objective is an informed start to a plan that can be maintained and reassessed as circumstances change.